In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
Lomefloxacin is a promising new difluorinated quinolone with good antimicrobial activity and favorable pharmacokinetic properties. The in vitro activity of lomefloxacin was compared to other quinolones, expanded spectrum beta-lactams, and gentamicin. The lomefloxacin MIC90 against multiply resistant strains of P. aeruginosa was 4 mcg/ml, comparable to norfloxacin and ofloxacin. Lomefloxacin was also active against methicillin-resistant S. epidermidis and JK corynebacteria. The role of lomefloxacin in the treatment of infections caused by multiresistant organisms remains to be determined in clinical trials.
DiVincenzo
C A
CA
Section of Infectious Diseases, Loyola University Medical Center, Maywood, Illinois.
Shatzer
K L
KL
Venezio
F R
FR
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004754:Enterobacter / Q000187:drug effects*; D004755:Enterobacteriaceae; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D015363:Quinolones; D013203:Staphylococcal Infections / Q000188:drug therapy; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000302:isolation & purification
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C053091:lomefloxacin; D009643:Norfloxacin